Edwards Lifesciences (FRA:EWL) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EWL Edwards Lifesciences Corp FRA:EWL
95 GF Score
Price €76.84
GF Value €82.50
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Edwards Lifesciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Edwards Lifesciences  (FRA:EWL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Edwards Lifesciences Cyclically Adjusted PB Ratio Related Terms


Edwards Lifesciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Cyclically Adjusted PB Ratio Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.88 12.46 10.46 8.93 7.89

Edwards Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.05 7.66 8.31 7.43 8.21

FRA:EWL vs BSX, DXCM, GEHC: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Cyclically Adjusted PB Ratio falls into.


FRA:EWL
95GF Score
Edwards Lifesciences Corp FRA:EWL
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Edwards Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Edwards Lifesciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=16.269/333.9520*333.9520
=16.269

Current CPI (Jun. 2026) = 333.9520.

Edwards Lifesciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.736 241.428 5.168
201612 3.912 241.432 5.411
201703 4.063 243.801 5.565
201706 4.070 244.955 5.549
201709 4.214 246.819 5.702
201712 3.913 246.524 5.301
201803 4.175 249.554 5.587
201806 4.318 251.989 5.722
201809 4.613 252.439 6.103
201812 4.409 251.233 5.861
201903 4.911 254.202 6.452
201906 4.928 256.143 6.425
201909 5.594 256.759 7.276
201912 5.891 256.974 7.656
202003 5.739 258.115 7.425
202006 5.501 257.797 7.126
202009 5.764 260.280 7.395
202012 5.988 260.474 7.677
202103 6.374 264.877 8.036
202106 6.947 271.696 8.539
202109 7.660 274.310 9.325
202112 8.223 278.802 9.850
202203 8.454 287.504 9.820
202206 9.173 296.311 10.338
202209 10.247 296.808 11.529
202212 8.944 296.797 10.064
202303 9.207 301.836 10.187
202306 9.720 305.109 10.639
202309 10.476 307.789 11.366
202312 10.120 306.746 11.018
202403 11.046 312.332 11.811
202406 11.626 314.175 12.358
202409 14.602 315.301 15.466
202412 16.510 315.605 17.470
202503 16.095 319.799 16.807
202506 15.369 322.561 15.912
202509 14.956 324.800 15.377
202512 15.158 324.054 15.621
202603 15.534 330.213 15.710
202606 16.269 333.952 16.269

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Edwards Lifesciences (FRA:EWL) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of €76.84 is trading 6.9% below its estimated GF Value™ of €82.50. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for FRA:EWL:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €82.50 vs. price of €76.84 (6.9% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the FRA:EWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
95GF Score

Get the complete analysis for FRA:EWL

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€76.84
Price
€82.50
GF Value